Tyra BiosciencesTYRA
NASDAQPharmaceuticals
No cached AI snapshot yet for TYRA.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
87 employees59.49M shares outstandinglisted 2021-09-15
Next earnings ~May 5, 2026
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Latest News
Showing market-wide stock news
Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Related Stocksin Pharmaceuticals
Ready to see the live AI view on TYRA?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing TYRA side-by-side with live signals.